Navigation Links
Shire Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases
Date:4/9/2013

d indicated there is less information/data available to help determine the standards of care for rare diseases (95% in the US, 90% in the UK agreed)
  • Although 90% of patients surveyed reported they had health coverage in the US:
    • 55% of US respondents incurred direct medical expenses not covered by insurance compared to 18% of respondents in the UK not covered by the National Health Service
    • 37% of respondents borrowed money from family and/or friends to pay for expenses in the US compared to only 21% of respondents in the UK
  • Due to the uncertainty, the lack of available information, resources, and economic strains, rare diseases take a major emotional toll on patients

    • Patient respondents reported several emotional difficulties managing their disease including depression (75% in the US, 69% in the UK agreed), anxiety and stress (86% in the US, 82% in the UK agreed), isolation from friends/family (65% in the US, 57% in the UK agreed), and worry based on future outlook of disease (90% in the US, 91% in the UK agreed)
      • For those rare disease patients where treatment options are limited, overall they worry more, feel more depressed, interact less and feel more isolated from family and friends, compared to patients with rare diseases for which there are available treatments

    Data Collection

    In January 2013, Shire HGT conducted online surveys over a four-week period among US and UK rare disease patients and their caregivers; physicians treating patients with rare diseases; payors who handle reimbursements for healthcare plans and government/institutions; and thought leaders in the rare disease space. Surveys were fielded through the market research agency, ORC International and also distributed by advocacy group partners Global Genes and
    '/>"/>

    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
    2. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
    3. Shire Reaches Agreement in Principle With U.S. Government
    4. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    5. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    8. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    9. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    10. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    11. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... NEW YORK , 27. März 2015 ... Vilcek Prize in Biomedical Science für seine ... wie Proteine zwischen Zellkompartimenten transportiert werden, sowie ... den Zellen zur Reaktion auf Stress nutzen, ... zusammenhängt. Dr. Walter ist Professor für Biochemie ...
    (Date:3/27/2015)... 27, 2015   SurePure, Inc . (OTCQB: ... today that the Company has completed the verification ... of SurePure ("SURP") securities on OTCQB, an electronic ... and development stage companies. On March ... eligibility requirements designed to improve marketplace integrity and ...
    (Date:3/27/2015)... 27, 2015 Working in collaboration with ... London , Richmond Pharmacology is the first ... 3 study for an investigational RNAi therapeutic being developed for ... the nerves and heart. Read press release ... Based at St Georges University of London ...
    (Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... and 12 months ended December 31, 2014.  ... million), or ($0.05) per share, for the three months ...
    Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
    ... 7,2008, Signalife received a deficiency letter from the ... that Signalife would need to,comply with the $6 ... AMEX Rules 1003(a)(iii). This notification was,triggered by the ... million, which previously exempted Signalife from meeting the ...
    ... First New Agent for CLL Patients Approved by the ... Cephalon, Inc. (Nasdaq:,CEPH) today announced that the U.S. ... for Injection for the,treatment of patients with chronic lymphocytic ... The American Cancer Society,estimates that more than 15,000 new ...
    ... live study setup and launch..., WAYLAND, Mass., ... bio-pharmaceutical clinical trials software, announces the,launch of its ... Trident,s unique parameter driven + custom pluggable design,leaps ... deliver a new era,of needed scalability, productivity, and ...
    Cached Biology Technology:AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 3Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 4Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 5Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3
    (Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
    (Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
    (Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
    Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
    ... percent of people with type 2 diabetes suffer kidney damage ... point they require either dialysis or kidney transplantation. Scientists have ... the glomeruli, blood vessels in the kidney, which spill the ... "albuminuria" do not prevent kidney failure. However, a ...
    ... identified a biological pathway connecting variation in the birds, aggression ... genome. The Proceedings of the National Academy of ... the experiments, conducted by the lab of neuroscientist Donna Maney ... research, which comprised behavioral observations of the study subjects in ...
    ... there is big business going on in their very small ... An international team of researchers, including Northern Arizona University ... the National Academy of Sciences that microbes, like many ... low. "Although hidden from the naked eye, microorganisms are ...
    Cached Biology News:Joslin finds metabolic clues to diabetic kidney failure 2Wild sparrow study traces social behaviors in the field to specific gene 2Wild sparrow study traces social behaviors in the field to specific gene 3Wild sparrow study traces social behaviors in the field to specific gene 4
    ... differences exist between the various commercial and ... slide used, the length and GC content ... the manufacturing protocol employed all influence the ... With all the different variables to ...
    ... Gel Stain combo offers these benefits: ... separately Offers a safer ... Eliminates risks to yourself, the environment and ... 100 bp to >30 kb. UltraPure Agarose is a ...
    This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
    ... contains 400 unique human proteins on ... The proteins, all extracellular proteins (EP) ... arrayed in quadruplicate for high-quality results. ... chip layout guarantee high validity and ...
    Biology Products: